Table 1.

Baseline demographics and clinical characteristics (safety analysis set).

 Patients, N = 1355
Sex
Male205 (15.1)
Female1150 (84.9)
Age, yrs, mean ± SD38.3 ± 13.64
Duration of SLE, yrs, mean ± SD9.3 ± 8.13
Duration of LN, yrs, mean ± SD6.7 ± 7.03
Antiphospholipid syndrome192 (14.2)
Previous treatment
Mizoribine311 (23.0)
Cyclosporine171 (12.6)
Azathioprine73 (5.4)
Cyclophosphamide72 (5.3)
Mycophenolate mofetil30 (2.2)
Pathologic type (ISN/RPS 2003 classification)
Type I9 (0.7)
Type II68 (5.0)
Type II+V7 (0.5)
Type III73 (5.4)
Type III+V26 (1.9)
Type IV-S64 (4.7)
Type IV-S+V15 (1.1)
TypeIV-G149 (11.0)
Type IV-G+V23 (1.7)
Type V156 (11.5)
Type VI1 (0.1)
Other28 (2.1)
  • Data are n (%) unless indicated otherwise. G: global; ISN/RPS: International Society of Nephrology/Renal Pathology Society; LN: lupus nephritis; S: segmental; SLE: systemic lupus erythematosus.